Rangering i aksjer
#28672
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Aksjekurs
$0.07339369
Sist synkronisert: 2026-08-18
Handel Resverlogix Corp. (RVX)
Pris RVX pris med markedsverdi på B
Markedsverdi av Resverlogix Corp.(RVX)
Markedsverdi: $25.24M
Per August 2026 har Resverlogix Corp. en markedsverdi på $25.24M. Dette gjør Resverlogix Corp. til det 28672nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Resverlogix Corp. fra 2004 til 2026
RVX sammenlignet med topp 5 mest populære stocks
| Pris på RVX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.301T
|
+20,999,338.36%
|
|
|
|
|
$4.634T
|
+18,357,012.00%
|
|
|
|
|
$4.143T
|
+16,412,357.35%
|
|
|
|
|
$3.589T
|
+14,219,233.93%
|
|
|
|
|
$2.857T
|
+11,317,728.88%
|
